Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
73 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), a subsidiary of Fosun International Limited is a biopharmaceutical and healthcare company that research and develops medical products. The companys business areas include healthcare services, medicine circulation, and medical diagnosis and medical equipment. Its medical products include oncology drugs, vaccines, metabolism and alimentary system drugs, central nervous system drugs, anti-infection drugs, cardiovascular and blood system, and crude drugs and intermediates.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal ra

  
Source:
Document ID
GDPH138889D
Country
Industry
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables42
  List of Figures61
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201662
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201681
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201691
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 2016102
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Medical Devices Deals, 2010 to YTD 2016121
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016134
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Pharmaceuticals &Healthcare, Deal Details1752
  Venture Financing171
    Ambrx Raises USD45 Million in Venture Financing172
    Saladax Biomedical Raises US$23 Million In Series D Venture Financing192
  Partnerships211
    Nature's Sunshine Products Forms Joint Venture with Fosun Pharma212
    Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics231
    Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma241
    Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin251
    Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments261
    Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug271
    Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group281
  Licensing Agreements291
    Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences291
    TB Alliance Enters Into Licensing Agreement With Fosun Pharma302
    Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug321
  Equity Offering331
    Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares331
    Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million342
    Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares361
    Amerigen Pharma to Raise USD35 Million in Private Placement of Shares371
    Nature's Sunshine Raises USD46 Million in Private Placement of Shares382
    Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million401
    Chindex International Completes First Closing Of Private Placement Of Common Stock For US$14 Million412
  Debt Offering431
    Shanghai Fosun Pharma Plans to Raise USD928 Million in Private Placement of Bonds431
    Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021441
    Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018451
    Shanghai Fosun Pharma Announces Public Offering Of Corporate Bonds To Raise Up To US$469.8 Million461
    Shanghai Fosun Pharma Completes Offering Of Notes Due 2015 For US$149 Million471
  Asset Transactions481
    Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma481
  Acquisition491
    Shanghai Fosun Pharma to Acquire 86% Stake in Gland Pharma for USD1.3 Billion492
    Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million511
    Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx522
    Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million541
    Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million551
    Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million561
    Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital571
    Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang581
    Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company591
    Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million601
    Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital611
    Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million621
    Fosun Pharma Acquires Additional Stake In Beijing Golden Elephant Pharmacy631
    Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group641
    Shanghai Fosun Pharma Acquires 75% Stake In Dalian Aleph Bio-medical651
    Shanghai Fosun Acquires 70% Stake In Shenyang Hongqi661
    Shanghai Fosun Pharma Acquires Minority Stake In Biosino Bio-Technology672
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Key Competitors691
Key Employees702
Locations And Subsidiaries721
  Head Office721
  Other Locations &Subsidiaries721
Appendix731
  Methodology731
  About GlobalData731
  Contact Us731
  Disclaimer731

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Shanghai-Fosun-Pharmaceutical-Group-Co-Ltd-600196-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-13678>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Shanghai-Fosun-Pharmaceutical-Group-Co-Ltd-600196-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-13678>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research